NCT01093261

Brief Summary

Traumatic brained injured (TBI) patients frequently suffered from glucocorticoid insufficiency that is associated with a raise in the rate of pneumonia. In a placebo-controlled, multi-center, double-blinded trial, treatment of glucocorticoid insufficiency (hydrocortisone associated with fludrocortisone) will be assessed for prevention of post trauma pneumonia in a population of severe TBI patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
336

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Aug 2010

Geographic Reach
1 country

18 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 25, 2010

Completed
4 months until next milestone

Study Start

First participant enrolled

August 1, 2010

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
Last Updated

September 14, 2017

Status Verified

September 1, 2017

Enrollment Period

2.3 years

First QC Date

March 23, 2010

Last Update Submit

September 13, 2017

Conditions

Keywords

traumatrauma brain injurymultiple traumahead traumahydrocortisonefludrocortisoneglucocorticoid insufficiency related to ICUadrenal Insufficiencypneumoniaintensive care unitshockneurological recovery

Outcome Measures

Primary Outcomes (1)

  • rate of hospital acquired pneumonia

    Presence of at least two signs (body fever greater than 38°C; leukocytosis greater than 12000/ml or leukopenia below 4000/ml, purulent pulmonary secretions) associated with the appearance of a new infiltrate or modification of an existing infiltrate on chest-X-ray. Confirmation by a lower respiratory tract sample using a quantitative culture with a predefined positive threshold. Hospital-acquired pneumonia was defined as a pneumonia that occurs 48 hours after admission, which was not incubating at time of admission (Am J Respir Crit Care Med 2005; 171, 388-416).

    day-28

Secondary Outcomes (10)

  • Neurological recovery

    1-year

  • other infections

    day-28

  • Organ failures

    day-28

  • Length of ICU stay

    6 months

  • Duration of mechanical ventilation support

    6 months

  • +5 more secondary outcomes

Study Arms (3)

Hydrocortisone and fludrocortisone

EXPERIMENTAL

Patients with glucocorticoid insufficiency

Drug: Hydrocortisone Fludrocortisone

Placebo

PLACEBO COMPARATOR

Patients with glucocorticoid insufficiency

Drug: Placebo

Controlled

NO INTERVENTION

Adapted glucocorticoid function

Interventions

Placebo: continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days.

Placebo

HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)

Hydrocortisone and fludrocortisone

Eligibility Criteria

Age15 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Trauma brain injury (Glasgow score below 8 and lesion on scanner)
  • Informed consent

You may not qualify if:

  • Tetraplegia
  • Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

University hospital

Amiens, France

Location

University Hospital

Angers, France

Location

University Hospital

Beaujon, France

Location

University hospital

Bordeaux, 33000, France

Location

University Hospital

Brest, France

Location

Universtiy Hospital

Caen, France

Location

University Hospital

Clermont-Ferrand, France

Location

University hospital

Créteil, 94000, France

Location

University Hospital

Créteil, France

Location

University Hospital

Grenoble, France

Location

University Hospital

Montpellier, France

Location

University Hospital

Nantes, France

Location

University Hospital

Nîmes, France

Location

European Hospital Georges Pompidou

Paris, 75000, France

Location

Saint Louis Hospital

Paris, 75000, France

Location

University hospital

Poitiers, 86000, France

Location

University Hospital

Strasbourg, France

Location

University Hospital

Toulouse, France

Location

Related Publications (2)

  • Asehnoune K, Roquilly A, Sebille V; Corti-TC trial group. Corticotherapy for traumatic brain-injured patients--the Corti-TC trial: study protocol for a randomized controlled trial. Trials. 2011 Oct 14;12:228. doi: 10.1186/1745-6215-12-228.

    PMID: 21999663BACKGROUND
  • Asehnoune K, Seguin P, Allary J, Feuillet F, Lasocki S, Cook F, Floch H, Chabanne R, Geeraerts T, Roger C, Perrigault PF, Hanouz JL, Lukaszewicz AC, Biais M, Boucheix P, Dahyot-Fizelier C, Capdevila X, Mahe PJ, Le Maguet P, Paugam-Burtz C, Gergaud S, Plaud B, Constantin JM, Malledant Y, Flet L, Sebille V, Roquilly A; Corti-TC Study Group. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir Med. 2014 Sep;2(9):706-16. doi: 10.1016/S2213-2600(14)70144-4. Epub 2014 Jul 24.

MeSH Terms

Conditions

Brain Injuries, TraumaticWounds and InjuriesAdrenal InsufficiencyPneumoniaMultiple TraumaCraniocerebral TraumaShock

Condition Hierarchy (Ancestors)

Brain InjuriesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemAdrenal Gland DiseasesEndocrine System DiseasesRespiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Karim ASEHNOUNE

    Nantes University Hospital

    STUDY CHAIR
  • Antoine ROQUILLY

    Nantes University Hospital

    PRINCIPAL INVESTIGATOR
  • Pierre François Perrigault

    CHU de Montpellier

    STUDY DIRECTOR
  • Pierre Albaladejo

    University Hospital, Grenoble

    STUDY DIRECTOR
  • Marc Leonne

    CHU de Marseille

    STUDY DIRECTOR
  • Olivier Langeron

    Assistance Publique - Hôpitaux de Paris

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Asehnoune

Study Record Dates

First Submitted

March 23, 2010

First Posted

March 25, 2010

Study Start

August 1, 2010

Primary Completion

November 1, 2012

Study Completion

December 1, 2012

Last Updated

September 14, 2017

Record last verified: 2017-09

Locations